Welcome to our dedicated page for Lexaria Bioscience SEC filings (Ticker: LEXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexaria Bioscience Corp. (LEXX) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, including registration statements, current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings provide structured insight into Lexaria’s DehydraTECH™ drug delivery platform business, intellectual property licensing model and capital markets activity.
Lexaria’s filings include Form S‑1 and Form S‑3 registration statements, which describe the company’s business, risk factors, financial statements and use of proceeds from securities offerings. Investors can review these documents to understand how Lexaria positions DehydraTECH as a patented oral drug delivery formulation and processing technology and how it organizes its operations around IP licensing and research and development.
Frequent Form 8‑K current reports document material events such as securities purchase agreements, registered direct offerings and concurrent private placements of warrants. Recent 8‑K filings detail offerings of common stock and warrants to institutional investors, the terms of those instruments, engagement agreements with placement agents and the intended use of proceeds for working capital, general corporate purposes and R&D programs.
Through these filings, readers can also track Lexaria’s agreements related to capital raising tools, such as sales agreements and their termination, as well as material transfer or licensing arrangements when they rise to the level of reportable events. Stock Titan enhances access to these documents with AI-powered summaries that highlight key terms, capital structure impacts and business implications, helping users quickly interpret complex legal and financial language.
For investors researching LEXX, this page offers real-time access to Lexaria’s SEC filings, including registration statements, 8‑Ks and related exhibits, along with AI-generated explanations of how each filing fits into the company’s broader DehydraTECH-focused strategy.
Lexaria Bioscience Corp. is registering up to 2,754,756 shares of common stock for resale by existing investors. These shares are issuable upon the exercise of outstanding warrants from a December 2025 private placement and related placement agent compensation. The company will not receive any money from stockholders’ resale of these shares.
If the warrants are exercised for cash, Lexaria would receive approximately $3.3 million in gross proceeds, which it plans to use for research and development, working capital and general corporate purposes. The company had 24,887,446 shares outstanding as of December 26, 2025, and its stock trades on the Nasdaq Capital Market under the symbol “LEXX”, with a last reported price of $0.809 per share on January 13, 2026.
Lexaria Bioscience Corp. has had its warrant class removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 notification stating that, under Section 12(b) of the Securities Exchange Act of 1934 and related rules, it has complied with its procedures to strike this warrant from listing and registration. The filing identifies only the company’s warrant as the affected class of securities and is signed on behalf of Nasdaq by an authorized officer.
Lexaria Bioscience Corp. reported a net loss of
Cash rose to
Lexaria Bioscience Corp. entered a securities purchase agreement with institutional investors and completed a combined registered direct offering and private placement, issuing 2,661,600 shares of common stock at $1.315 per share and 2,661,600 warrants with a $1.19 exercise price for gross proceeds of approximately $3.5 million before fees.
The shares were sold under an effective shelf registration, while the warrants and their underlying shares were issued in a private placement under Securities Act exemptions, with a 4.99% beneficial ownership cap that can be increased to up to 9.99% on notice. Lexaria agreed to file a resale registration statement for the warrant shares within specified deadlines, accepted a 30-day restriction on additional equity issuance and new registration filings (subject to exceptions), and plans to use net proceeds for working capital and other general corporate purposes. H.C. Wainwright & Co. acted as placement agent, earning a 7.0% cash fee, 93,156 warrants with a $1.6438 exercise price, and specified expense reimbursements.
Lexaria Bioscience Corp. is offering 2,661,600 shares of common stock at $1.315 per share in a primary registered direct sale to institutional investors. Gross proceeds are expected to be $3,500,004.00, with net proceeds of about $3.0 million after placement fees and expenses, which the company plans to use to advance research and development, fund working capital and for other general corporate purposes.
Alongside the stock sale, Lexaria is issuing in a separate private placement warrants to purchase up to 2,661,600 additional shares at an exercise price of $1.19 per share. If all of these private placement warrants are exercised for cash, the company would receive roughly $3.1 million in additional net proceeds.
Shares outstanding were 22,225,846 as of December 14, 2025 and are expected to become 24,887,446 after this offering, excluding any warrant or option exercises. Based on a pro forma as adjusted net tangible book value of $0.35 per share as of August 31, 2025, investors buying in this offering face immediate dilution of $0.97 per share, and the company highlights risks related to stock price volatility, Nasdaq listing compliance and potential future dilution.
Lexaria Bioscience Corp. is updating a resale registration covering up to 314,287 shares of common stock issuable upon exercise of outstanding warrants previously issued in its February 2024 financing and related placement-agent compensation. The company will not receive proceeds from stockholders’ sales of these shares, but could receive approximately $725,036 in cash if all related warrants are exercised. Most of the originally registered warrant shares have already been exercised, leaving only these 314,287 shares covered. Shares of common stock outstanding were 22,225,846 as of December 4, 2025; this reflects the then-current share count, not the amount being registered.
Lexaria is a biotechnology company developing its DehydraTECH drug-delivery technology to improve oral delivery of GLP‑1 and GIP diabetes and weight-loss drugs, CBD and other molecules. Human pilot and chronic studies and animal work described here report higher or steadier drug levels, improved weight and blood-sugar control, and fewer gastrointestinal side effects for DehydraTECH-enhanced semaglutide, tirzepatide, liraglutide and CBD compared with Rybelsus, Zepbound, Saxenda and other controls, with several findings based on small samples.
The company also notes an FDA Study May Proceed letter supporting a planned Phase 1b hypertension trial of DehydraTECH‑CBD, a September 2025 registered direct and private placement of 2,666,667 shares at $1.50 and 2,666,667 warrants at $1.37, and the bankruptcy of cannabis licensee Hill Inc., whose DehydraTECH rights and small equity stake are being assessed. Its auditor’s latest report includes a going concern explanatory paragraph, highlighting financing and execution risk as Lexaria advances its pipeline.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company focused on improving oral delivery of drugs using its patented DehydraTECH technology, which combines active pharmaceutical ingredients with long-chain fatty acids to boost bioavailability and tolerability. The platform targets GLP‑1/GIP drugs, CBD, nicotine, antivirals and other molecules across indications such as diabetes, obesity, hypertension, epilepsy and heart disease, and can be used in multiple oral dosage forms.
The company reports an extensive intellectual property portfolio with 56 granted patents worldwide across several families, including recent protections for GLP‑1/GIP diabetes and obesity treatments, epilepsy, diabetes, nicotine and food applications. Lexaria spent $8.2 million on R&D in fiscal 2025, advancing multiple human and animal studies of DehydraTECH-enhanced GLP‑1/GIP drugs and CBD, and has an FDA-cleared IND and 505(b)(2) pathway for a Phase 1b hypertension trial using DehydraTECH‑CBD.
At August 31, 2025, Lexaria had $1.8 million in unrestricted cash and cash equivalents versus $1.5 million in current liabilities and disclosed substantial doubt about its ability to continue as a going concern without additional financing, partnerships or cost reductions. As of November 25, 2025, there were 22,225,846 common shares outstanding, and the non‑affiliate equity market value at the prior second quarter date was about $24.6 million.
Lexaria Bioscience Corp. filed a Form S-1 registering for resale up to 2,760,000 shares of common stock issuable upon exercise of outstanding warrants from the September 2025 Offering and an engagement with H.C. Wainwright & Co. The company is not selling any shares in this offering and will not receive proceeds from any resale by the selling stockholders. If the warrants are exercised for cash, Lexaria would receive approximately $3,828,333.
Common stock outstanding was 22,225,846 shares as of October 9, 2025, and would be 24,985,846 shares assuming exercise of all registered warrants. The prospectus outlines standard methods of sale by selling stockholders and notes Nasdaq listings under “LEXX” and “LEXXW.” Risk factors include potential price pressure from resales and dilution from warrant exercises, and a going‑concern note citing $4.6 million in cash and cash equivalents against $1.5 million in current liabilities as of May 31, 2025.
Lexaria Bioscience Corp. filed a Form D reporting a completed Regulation D offering under Rule 506(b) for total proceeds of $4,000,000. The filing states the entire offering amount was sold and no remaining securities are available. The offering included registered shares combined with unregistered warrants and a 7% sales commission paid, totaling an estimated $280,000.
The issuer lists its principal place of business in Kelowna, British Columbia, and identifies multiple executives and directors at that address. The offering involved 5 investors, was not connected to any business combination, had a minimum outside investment of $0, and used H.C. Wainwright & Co. as the associated broker-dealer. No proceeds were allocated to payments to named officers, directors, or promoters per the filing.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
